STEP HFpEF study

STEP HFpEF (Semaglutide Treatment Effect in People with Obesity, Heart Failure with Preserved Ejection Fraction)

This study will investigate how well a new drug called semaglutide works at helping people lose weight and reduce symptoms of heart failure.

Participation in the study will last for 59 weeks.

It is being carried out in Greater Manchester by a team cased at the Manchester Heart Centre, part of Manchester University NHS Foundation Trust.

Further reading

• Mikhail Kosiborod, Steen Zabell Abildstrøm, Borlaug, B.A., Butler, J., Rasmussen, S., Davies, M.J., G. Kees Hovingh, Kitzman, D.W., Marie L.S. Lindegaard, Daniel Vega Møller, Shah, S.J., Marianne Bach Treppendahl, Verma, S., Abhayaratna, W.P., Ahmed, F., Chopra, V., Ezekowitz, J.A., Fu, M., Ito, H. and Lelonek, M. (2023). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. The New England Journal of Medicine, 389(12). doi:https://doi.org/10.1056/nejmoa2306963.
• Manchester University NHS Foundation Trust (2023). Spotlight On: Dr Fozia Ahmed, Consultant Cardiologist. [online] Research & Innovation. Available at: https://research.cmft.nhs.uk/news-events/spotlight-on-dr-fozia-ahmed-consultant-cardiologist [Accessed 22 Dec. 2023].